Ocrevus (ocrelizumab) eliminated the immunity, acquired through vaccination, to the varicella-zoster virus — the virus that causes chickenpox and shingles — in a man with relapsing-remitting multiple sclerosis (RRMS), a case study reported.
Its authors recommended that MS patients being treated with Ocrevus be retested for immunity against the varicella-zoster virus.
Ocrevus (developed by Genentech) is an antibody-based therapy approved for patients with relapsing MS and primary progressive MS (PPMS). It is designed to suppress immune system attacks on the myelin sheath, the coating that protects nerve fibers.
The treatment targets mature B-cells, a type of immune cell that produces a protein called CD20 on its surface. While depleting mature B-cells, Ocrevus has been shown to preserve the ability to generate new B-cells as well as maintain pre-existing immunity acquired from previous infections or vaccinations.
But evidence shows that some patients given vaccines to protect against the influenza virus or pneumococcal bacteria lose such immunity after Ocrevus treatment.
https://multiplesclerosisnewstoday.c...t-case-report/
Its authors recommended that MS patients being treated with Ocrevus be retested for immunity against the varicella-zoster virus.
Ocrevus (developed by Genentech) is an antibody-based therapy approved for patients with relapsing MS and primary progressive MS (PPMS). It is designed to suppress immune system attacks on the myelin sheath, the coating that protects nerve fibers.
The treatment targets mature B-cells, a type of immune cell that produces a protein called CD20 on its surface. While depleting mature B-cells, Ocrevus has been shown to preserve the ability to generate new B-cells as well as maintain pre-existing immunity acquired from previous infections or vaccinations.
But evidence shows that some patients given vaccines to protect against the influenza virus or pneumococcal bacteria lose such immunity after Ocrevus treatment.
https://multiplesclerosisnewstoday.c...t-case-report/
Comment